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Interaction of sulphonylurea derivatives with 
vascular ATP-sensitive potassium channels in humans
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Summary Cardiovascular adenosine-5 '-triphospha- 
te-sensitive potassium (KATP) channels have been re­
ported to play an important role in endogenous car­
dioprotective mechanisms. Sulphonylurea derivatives 
can inhibit these cardioprotective mechanisms in ani­
mal models. We investigated whether therapeutic 
concentrations of sulphonylurea derivatives can 
block vascular KATP channels in humans. The forearm 
vasodilator responses to administration of the spe­
cific Katp channel opener diazoxide into the brachial 
artery of healthy male volunteers were recorded by 
venous occlusion plethysmography. This procedure 
was repeated with concomitant intraarterial infusion 
of:l)  the sulphonylurea derivative glibenclamide 
(0.33 or 3.3 [xg ■ min“ 1 • dH, both n = 1 2 ), 2) the new  
sulphonylurea derivative glimepiride (2.5 (.ig • min-1 • 
dl'1, n = 12) or 3) placebo (n = 12). The effects of glib­
enclamide on the vasodilator responses to sodium ni- 
troprusside were also studied (n = 12). Glibenclamide
significantly inhibited the diazoxide-induced increase 
in forearm blood flow ratio (ANO VA with repeated 
measures: pcO .O l). During the highest diazoxide 
dose this ratio (mean ±  SEM) was lowered from 
892 ± 1 6 5  to 449 + 105%, and from 1044 + 248 to 
663 ± 114 % by low- and high-dose glibenclamide, re­
spectively. In contrast, neither glimepiride nor pla­
cebo attenuate diazoxide-induced vasodilation. Fur­
thermore, glibenclamide did not affect nitroprus- 
side-induced vasodilation. We conclude that ther­
apeutic concentrations of the classical sulphonylurea 
derivative glibenclamide result in significant block­
ade of vascular KATP channels in humans. The newly 
developed glimepiride seems to be devoid of these 
properties. [Diabetologia (1996) 39:1083-1090]
Keywords Glibenclamide, glimepiride, diazoxide, 
forearm blood flow, cardioprotection, sulphonylurea 
derivatives, potassium channels, vascular.
Sulphonylurea (SU) derivatives have represented the 
backbone of non-insulin-dependent diabetes mellitus 
(NIDDM) therapy for several decades [1]. These 
drugs exert their primary effect by closing so-call- 
ed adenosine-5'-triphosphate-sensitive potassium
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(KATp) channels in the beta cell of the pancreas, 
which promotes an influx of calcium with subsequent 
stimulation of insulin release [2 ], Recent investiga­
tions have shown that the cardiovascular system also 
shares functional K ATP channels [3]. Under physio­
logical circumstances these channels are closed or in­
active [4]. During hypoxia and/or ischaemia, the in­
tracellular concentration o f ATP falls which is a di­
rect signal for KATP channels to open. The subsequent 
efflux of potassium and hyperpolarization of the cell 
membrane induces a shortening of the action poten­
tial in the myocardium and a relaxation of the vascu­
lar smooth muscle cell [5, 6 ]. Animal experiments 
have shown that these mechanisms play a role in the 
protection of the myocardium against ischaemia and 
reperfusion damage [7].
Table I. Characteristics of the healthy volunteers
I
lì
Age (years)
Weight (kg)
Height (m)
Body mass index (kg/nr)
Systolic blood pressure (mm Hg)a 
Diastolic blood pressure (mmHg)1' 
Heart rate (bpm)
Pilol Glibenclamide Glibenclamide Cilimcpiride Time conimi
Data are presented as means (± S D ) . 1 Sphygmomanometrically obtained blood pressure alter 5 min supine rest
Vasodilator
low-dose high-dose control
4 12 12 12 12 12
24 ± 5 27 ± 9 27 ±7 30 ± 11 33 > 4 .'( i y. <)
67 ± 6 75 ± 9 76 ± 7 7l) ± 8 SI * 12 75 •: 11
1 .SO ±0.07 1,79 ± 0.06 l.tSl ±0.07 1.81 tufo 1.82 ). 0.07 I.N4 1 O.Od
i l  + l 23 ± 2 M S  ’  f t w 24 * ■>'  - » mn 24 *. 2 22 3
124 ± 3 127 ± 9 125 ± 6 128 ± 1 130 f 8 12.S 1 4
71 ± 6 67 ± 9 m  ± io 74 ± 11 71 M l 75 11 ,
68 ± 3 64 ± 4 05 ± 7 62 64 r 7 f>7 8
Interestingly, vascular KAT)> channels can be acti­
vated pharmacologically by KAT1, channel-opening 
drugs such as diazoxide, pinacidil, cromakalim and 
bimakalim [4]. These drugs have been shown to inter­
act directly with the KAn, channel without interfering 
with the SU receptor [8 ]. Hence, [■'Hjglibenclamide 
binding to the solubilized SU receptor was not inhib­
ited by diazoxide [9], whereas glibenclamide binding 
to SU receptors of intact cells can indirectly be inhib­
ited by KA-|i> channel openers [10]. In animal experi­
ments, glibenclamide has been shown to inhibit the 
vasodilator as well as the cardioprotective responses 
to KAT[> channel-opening drugs [7, 11], Moreover, 
SU derivatives have been demonstrated to attenuate 
the vasodilator response to an ischaemic stimulus
[1 2 ] and to abolish the protective effects of myocar­
dial ischaemic preconditioning [13, 14]. In theory, 
the aforementioned observations may implicate 
harmful cardiovascular effects of SU derivatives 
when used under conditions of ischaemia in patients 
with NIDDM . However, up to now no data in hu­
mans on the cardiovascular effects of SU derivatives
at clinically relevant concentrations are available. 
Therefore, we investigated the ability of the SU
derivative glibenclamide to reduce the vasodilator re­
sponse to KAT[. channel-activalion in man. Further, 
we included studies with the newly developed SIJ de­
rivative glimepiride which has been shown lo be de­
void of vascular K,vn> channel binding properties in 
animal models [15, 16].
Subjects and methods
The nim of this study was lo investigale the putative inhibitory 
effects o f  glibenclamide on the K.vn, channel-mediated vasodi­
lation by diazoxide. In order to address the hypothesis of our 
study, the perfused forearm technique was used [17J. The study 
protocol was approved by the local ethics committee, and ail 
participants gave written informed consent before entering 
the study. A ll experiments were performed in healthy male 
non-smoking volunteers with a normal medical history, physi­
cal examination and blood pressure. The characteristics of the 
subsets o f  volunteers are listed in Table I. Each volunteer par­
ticipated in only one experiment and was instructed to abstain 
from caffeine-containing beverages and alcohol at least 24 h 
before the experiment. Furthermore, they were asked to eat a
light meal at 2 h before the experiment was started and to ab­
stain from further food intake until after the experiment. Fore­
arm volume was measured by water displacement. The experi­
ments were performed with the subjects in the supine position 
in a quiet temperature controlled room (22  (') to ensure that 
forearm blood flow (FBF) predominantly referred to forearm 
muscle perfusion ( 1 <S|.
(ilihcncltiintdc stitily. ‘Hie effects of glibenclamide on the diaz- 
oxide-mediated vasodilation were studied. A cannula was in­
serted into the brachial arterv (Anniocath. .’I) naiiue: Deseret
Medical Inc., Bccton Dickinson, Sandv, Utah, U SA ). For
%
some of the protocols an anteeubital vein o í  the left and the 
right arm was also eannulated. Alter an equilibration period 
of 45 min, a 35 min intraartcrial infusion of placebo (154 
mmol/l NaCT) was started. After Iti min. baseline measure­
ments of blood pressure, heart rate and bilateral FBF were la­
ken during the concomitant intraartcrial placebo infusion. 
Then, a dose-responsc curve of the vasodilator effects of diaz­
oxide was made (three intraartcrial dosane*: 0,25, 0.75, 
2.25 mg min 1 per dl of forearm volume, 5 ruin per dose). All 
drugs were infused at a volume rate of 50 ul min r * dl 1 using 
an automated syringe infusion pump (type STC 521; Terumo 
Corp.. Tokyo, Japan). Blood pressure was measured via the in- 
traarterial line using a Hewlett Packard monitor (type 7S353B; 
Böblingen. Germany). FBF was measured by F.(‘( i  triggered 
venous occlusion mercury-in-silastic strain gauge plethysmog­
raphy (Hokanson FC4; 1) , F. Hokanson, lue.. Issaquah, 
Wash., USA), During all recordings of the FBF. the hand circu­
lation was completely occluded by a wrist cuff inflated 
KlOmmllg above the systolic blood pressure to be sure that 
measurements onlv referred to the forearm skeletal muscle
*
vascular bed [H)|. After a subsequent equilibration of 60min  
to allow parameters to return to baseline levels, baseline values 
during concomitant intraartcrial infusion of placebo were 
again recorded. Then a second dose response c u n e  was made 
in 12 subjects, but with concomitant infusion into the brachial 
arterv of glibenclamide instead of placebo.
In a pilot study with four volunteers, we tul used five dos- 
aues of elibenclamidc (0.1, 0 33. 1.0 . 3.3. HUIuu min 1 dl \
10 min per dose) into the brachial arten , and sampled blood 
from the neiiihhourinu vein to determine which infusion rate
H  »
would lead to regional serum concent rat ions ot about 200  ng/ 
ml as maximally occurs after oral administration o f  5 mg glib­
enclamide to diabetic patients ¡20, 21 J. These five infusions re­
sulted in regional concentrations of 4 3 »  15, 13X139, 
564 t  143, 1926 * 363 and 5141 * 1207 ng ml, respectively. Hie 
second dose of glibenclamide 10.33 fig min 1 dl T was chosen 
for the final experiments. In order to investigate possible dose- 
dependent effects of glibenclamide on the d ia /o \ide-m cdiaied  
vasodilation, we also used a dose ot ulibenelamide 10 times 
higher (3.3 \ii\ min 5 ill 1 ) in another 12 subjects.
I -  < r -  —  -  v « v * 4  j  T U l l  V W i l* i(J o5
V l m i o u s  blood samples troni the non-experimental arm 
were taken for insulin and C-peptide as well as for glibencla- 
mide determinations before and at the end of glibenclamide 
infusion. After  each dia/oxide infusion venous blood samples 
from the experimental side were taken for the determination 
of local glibenclamide concentrations. At all these time points 
the plasma glucose concentration was also measured. Glucose 
was measured immediately by an Acculrend glucose analyzer 
(type 1284851; Boehringer, Mannheim, Germany).
Because of the long half-life, high protein binding [20, 21] 
and possible incorporation of SU derivatives in the plasma 
mem brane  [22|, randomization of placebo and SU derivative 
was noi possible because of carryover effects.
(itimcpiride study. Apart  from glibenclamide, we also studied 
the newly developed SU derivative glimepiride. Glimepiride 
strongly resembles glibenclamide on a molecular basis [23], 
but pharmacodynamicallv Ihev have to be distinguished. Like 
the o ther  SU derivatives, glimepiride also stimulates insulin se­
cretion from the beta cell of the pancreas [24], but glimepiride 
and glibenclamide have different binding sites in the pancre­
atic beta cell |25, 26). Furthermore,  in contrast to glibencla­
mide. animal models have not shown any interaction of glim­
epiride with vascular KAn, channels [15, 16],
To investigate whether glimepiride is devoid of inhibitory 
effects on the K AJ )* channel-mediated vasodilation by diazox­
ide, the above-described protocol was performed with glimepi­
ride instead of glibenclamide (// = 12). Maximal concentra­
tions after regular once daily oral administration of 4 mg glim­
epiride to N ID D M  patients were about 300 ng/ml. In our ex­
periments we used a dose of 2.5 pg • min 1 • dl 1 of glimepiride, 
which is thought to result in regional concentrations above 
the therapeutic  range as seen during treatment of NIDD M
["M ^71I  f c v  *  p *  a -  r *  1 1
Insulin and C-peptide were determined in venous blood 
samples collected in chilled glass tubes coated with lithium- 
heparin. The blood was centrifuged at 3000 routes/m in for 
10 min. Then plasma was frozen at - 2 0 °C. In these samples in­
sulin and C-peptide were determined in our laboratories using 
specific RIAs. C-peptide was measured with a standard kit 
(D. P. C., Los Angeles, Calif., USA) and insulin with a proce­
dure using standard and tracer prepared from monocompo- 
nenl human insulin (NOVO, Zoeterwoude, The Netherlands).
Calcul citions. Forearm vascular resistance (FVR) was calcu­
lated as the quotient of mean arterial pressure (M AP) and 
FBF. The ratio of experimental to non-experimental FBF was 
calculated to correct for systemic changes due to time or a ro u ­
sal in order to refer only to changes induced by local infusions 
[30]. For each dose of diazoxide and SNP, FBF registrations of 
the last 2 min of infusion were averaged to one mean rep resen­
tative value. Likewise, absolute and percentage changes from 
baseline were calculated. In the same manner values for F V R  
and FBF ratio were obtained.
Statistical analysis
The results were analysed statistically by an analysis of var i­
ance (ANOVA) with repeated measures over all vasodilator 
dosages. A y;-value of less than 0.05 was considered statistically 
significant. Because of significant differences in baseline val­
ues this analysis was performed on the percentage changes 
from baseline for the FBF ratio, but also for the FBF and 
FVR, followed by post-hoc f-tests when A NO VA  was signifi­
cant. Values presented are means ± SEM unless indicated o th ­
erwise,
Time control study. In order to exclude any influence of time or 
the repeat o f  the diazoxide infusions, a time-control study was 
performed ili ano ther  12 subjects. 'This study was identical to 
the previous studies, except that placebo was not replaced in 
the second part,  resulting in two dose-response curves of diaz­
oxide with concomitant intraartcrial infusion of placebo.
Vasotlihitor control study. To show that glibenclamide had spe­
cific effects on KAn. channel-mediated vasodilation, we inves­
tigated the effects of glibenclamide on the vasodilator re­
sponse to sodium nitroprusside (SNP) in another  12 subjects. 
This part was identical with the low-dose glibenclamide study, 
except that the three intraartcrial diazoxide dosages were re­
placed by three intraartcrial dosages of SNP (0.06, 0.2,
0.6 jig min 1 ■ dl l, 5 min per dose). In this series, glibencla­
mide serum concentrations as well as glucose, insulin and C~ 
pepiide concentrations were determined before and after glib­
enclamide infusion.
Humoral parameters, For glibenclamide and glimepiride deter­
minations venous blood samples were collected in glass tubes 
without additives. After  20 min the blood was centrifuged at 
3000 rouies/min for 10 min. Then serum was frozen at - 2 0 ° C . 
In these serum samples drug concentrations were determined 
at the laboratories of 1 ioechst AG, Frankfurt, Germany, Glib­
enclamide was determined, using a validated specific radioim­
munoassay (R IA )  [28]. The detection limit was 1-3 ng/ml and 
concentrations higher than 200 ng/ml were diluted be I ore be­
ing measured according to the s tandard procedure. Glimepi­
ride was de term ined  by high performance liquid chromatogra­
phy (I IPl.C) [2 %  'Hie limit of quantification was 10 ng/ml, and 
the detection limit was 5 ng/ml*
Results
Vascular effects o f  diazoxide. To characterize the dia­
zoxide-induced changes, the data of 48 subjects in 
which the first dose-response curve of diazoxide was 
performed were pooled. In Table 2 the effects of diaz­
oxide infusions into the brachial artery on FBF, FVR, 
FBF ratio, MAP and heart rate are shown. Diazoxide 
infusions induced a dose-dependent forearm vasodi­
lator response. The FBF and FVR on the non-experi­
mental side remained unchanged. Diazoxide-induced 
changes in MAP and heart rate were small but statis­
tically significant and occurred only during the high­
est dose. In 12 subjects a time-control study was per­
formed. From baseline values (1.2 ±0.1), FBF ratio 
increased 1.4 ±0.3, 2 .8  ±0 .6  and 6.3 ± 1 .4  during a
first dose-response curve of diazoxide. After 1 h of 
equilibration, FBF ratio had returned towards base­
line levels (1.7 ±0.2) after which it increased 1.5 ±
0.3, 2.5 ±0.5  and 7.6 ±1.5 during a second dose-re­
sponse curve. These absolute changes as well as the 
percentage changes from baseline during the first 
and second dose-response curves showed no signifi­
cant differences (/; = 0.63 and p  = 0.51 respectively).
Vascular effects o f  sulphonylurea derivatives. Ten min­
utes of the single intraarterial infusion of glibenclamide
AáiJkMv j** i wuil;u mtui iU •+0 mu»jccis ai naseune anu uurmg uiazoxide with p lacebo infusions
n = 48 Baseline I D iazo x id e  0.25
FBF-ex peri men tal (ml • min 1 
FBF-control (ml • min"1 ■ dl“1) 
FBF ratio“
FVR-expe riment al (AlJ)iv 
FVR-control (AU)
MAP (mm Hg)a 
Heart rate (hpm);l
l\: id l 1) 1.9 ±0.1
1.7 + OJ 
1.3 ±0.1 
51.7 ±2.7  
()3.5 ± 5 .1 
85 ± 1
58 ± I
4 .0± 0 .2h 
1.7 ± 0.1
2.9 ± 0.2b
25.2 ± l.Cf' 
66.9 ±5.7 
85 ± 1
59 ± I
Diazoxide 0.75 Diazoxide 2.25 Baseline :
6.7 ± 0.4" 14.: ± i.o" 3.0 ± 0.2"
!.(> ± 0.1 !.(< 1 (1.1 1.7 ± 0.1
4.« i  0.4" 11.() J 1 .3” 13)±0.|"
ld.3 ± 1.31' 8.0 ,t o.'l'' 37.0 ± 2.(i
63,9 ± 5.8 WM (>,? (>2.‘) ± 4.5
84 ± 1 >S2 1 " ■SO ± 1
(i() ± 1 us i. :" 5') ± 1
Dala ure mean ± SEM. Forearm blood flow (FBF) and forearm 
vascular resistance (FVR in arbitrary units, A U ), both at the 
experimental and non-experimental control side, and mean 
arterial pressure (MAP) and heart rate (in beats per minute.
bpm ) . 1 Repeated measures A N O V A  over three diazoxide d o­
sages p <  0,05; Bonlerroni corrected /-test vs baseline I 
p  < 0.005
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Fig. L The left panel shows mean ( ± SEM) absolute FBF ra­
tio's at baseline and durimi intraarterial infusion of the three 
diazoxide dosages (0.25,0.75,2.25) with concomitant intmarto­
riai infusion of placebo ( # ) ,  or with concomitant intraarterial 
infusion of low-dose glibenclamide (Q ).  'I’he right panel shows 
the corresponding mean (± S H M ) percentage changes from 
baseline in FBF ratio. ( | )  Placebo; ( □ )  low-dose glibencla­
mide. The /¿-value refers to ANO VA with repeated measures 
over the complete dose-response curves
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the corresponding mean ( J SEM) percentage changes from 
baseline in FBF ratio. ( ■ )  Placebo; (|_j) glibenclamide. The 
/rvalue refers to A N O V A  with repeated measures over the 
complete dose-response curves. NS, not significant
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Effects o f  SU derivatives on vasodilator responses, hi 
Figure I and 2 it is dearly seen that absolute values 
of the FBF ratio (left panels) and its percentage chan­
ges from baseline (right panels) in response to diaz­
oxide infusions were lower during co-infusion of glib- 
enelamide than during co-infusion of placebo (low- 
dose/) ~ 0 .0 1 , high-dose/) --- 0 .0 2 ), indicating a statisti­
cally significant reduction of the vasodilator responses 
to dia/.oxide during glibenclamide infusion. In Table 3 
this is also shown lor the changes in FBFand FVR.'Hie 
reductions in diazoxide-mediated vasodilation bv low- 
and high-dose gUbenelnmide were not significantly 
different from each other (/) -= 0 .W). Post-hoe Mests 
showed a significant inhibition of vasodilation bv 
low-dose glibenclamide induced only during the high­
est diazoxide dose (/) O.OOiS), whereas the high-dose 
tllibenelamide sitinifieantlv inhibited the lowest 
{p < (UK) I ) and the middle (/>  ^ 0.04) dia/oxido close.
Figure 3 shows that, in contrast to glibenclamide, 
alone (0.33 ¡.tg • min 1 • di'"1) did not alter the FBFratio the new SU derivative glimepiride had no inhibitory 
(change; 0.02 ± 0.08). This number did not differ statis- effects on the vasodilator responses to diazoxide. Fig- 
tically Irom the change induced by placebo in the time- ure 4 shows that low-dose glibenclamide did not af- 
conlrol series (0.04 ± 0.26). The same was true for the feel the vasodilator responses to the KAn> channel in- 
high-dose glibenclamide and the glimepiride series. dependent vasodilator SNR
We did not observe any effect of the SU derivatives on Similar to the first series of diazoxide infusions 
blood pressure and heart rale. (Table 2)* sliuht champes in MAP and heart rate
Fig.2. H ie  left panel shows mean ( ± SEM) absolute FBF ra­
tio's at baseline and during intraarterial infusion o f  the three 
diazoxide dosages {0.25,0.75,2.25) with concomitant intraarte­
rial infusion of placebo ( # ) ,  or with concomitant intraarterial 
infusion of high-dose glibenclamide (O ), The right panel 
shows the corresponding mean ( ± S E M ) percentage changes 
from baseline in FBFratio. ( ■ )  Placebo; ( Q )  high-dose glib­
enclamide. The /¿-value refers to A NO VA with repeated m ea­
sures over the complete dose-response curves
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Fig.4. The left panel shows mean (±SEM) absolute FBF ra­
tios at baseline and during intraarterial infusion of the three so­
dium nitroprusside dosages (0.06,0.2,0.6) with concomitant in- 
traarteriaî infusion of placebo (# ), or with concomitant intra­
arterial infusion of low-dose glibenclamide (Q). The right pa­
nel shows the corresponding mean (± SEM) percentage chan­
ges from baseline in FBF ratio. ( | )  Placebo; (□) glibencla­
mide. The />■value refers to ANOVA with repeated measures 
over the complete dose-response curves. NS, not significant
occurred during the highest diazoxide dose in this 
second part. These changes showed no differences 
between the protocols. Moreover, the FBF and the 
FVR in the non-experimental arm showed no statisti­
cally significant changes indicating that the systemic 
alterations in MAP and heart rate could not have 
contributed to the changes in FBF of the experimeii“ 
tal arm*
Changes in humoral parameters .  Low-dose glibencla­
mide did not affect systemic plasma glucose (from 
4.6 ± 0.4 mmol/l before to 4.5 ± 0.2 nimol/l at the end
of plasma insulin (from 117.4 ± 9 .4  to
109.4 ±7 .9  pmol/1) or plasma C-peptide concentra­
tions (from 0.79 ±0.07 to 0.79 ±0.03 pmol/1). How­
ever, the high glibenclamide dose significantly re­
duced plasma glucose from 4.7 ± 0 .2  to 4.0 ± 
0 .2  mmol/l (p < 0 .0 0 1 ), and raised plasma insulin and 
C-peptide concentration from 74.9 ± 15.1 pmol/1 and 
0.46 ±0.05 nmol/1 to 175.7 ±28.8 pmol/1 (pcO.Ol) 
and 0.75 ± 0.09 nmol/1 (p < 0.01), respectively. In the 
glimepiride series no significant changes in plasma 
concentrations of glucose (from 4.5 ± 0 .1  to 4.5 ± 
0.1 mmol/l), insulin (from 57.6 ± 8 .6  to 45.4 ±6 .5  
pmol/1) or C-peptide (from 0.55 ± 0.04 to 0.48 ± 0.04 
nmol/1) occurred.
After 10 min of the single infusion of low-dose 
glibenclamide, the regional serum concentration av­
eraged 193 ± 41 ng/ml, which fell to 48 ± 6  ng/ml dur­
ing the highest vasodilator dose as a result of dilution 
(n = 12). At the end of the experiment the systemic 
glibenclamide concentration had accumulated to 
17 ± 2 ng/ml. For the highest glibenclamide dose, the 
regional forearm concentrations at the end of the 
three diazoxide dosages were 881 ±94, 508 ± 59  and 
266 ± 3 2  ng/ml, respectively, whereas the systemic 
concentration at the end of the protocol averaged 
152 ± 6  ng/ml. For glimepiride the local forearm con­
centrations were: 8.15 ±97, 515 ±72, 325 ±25 ng/ml
aller the three respective diazoxide dosages, whereas 
the systemic concentration averaged 194 ± 7  ng/ml at 
the end of the protocol.
Discussion
The present study convincingly shows that the classi­
cal SU derivative glibenclamide is able to interact 
with vascular K ATi> channel-activity in man. The in­
traarterial dosages of glibenclamide significantly in­
hibited the forearm vasodilator response to activa­
tion of KAT|> channels by diazoxide. This attenuation 
could not be attributed to lime effects since the re­
peat of diazoxide infusion resulted in an unaltered di-
intraarterial administration of glimepiride leads to lo­
cal concentrations of 325 ± 25 ng/ml or higher, which 
are much higher concentrations than reached in the 
low-dose glibenclamide study, and are also higher 
than concentrations needed svstemieallv to induce in-
W *
sulin production [23, 24).
Compared with the low glibenclamide dose, the 10 
times higher dose of glihenclamido was not associ- 
ated with a more pronounced block of diazoxide-in- 
duced vasodilation. The blockade bv the low dose 
was far from complete; therefore, the higher dose 
was expected to further inhibit the response to dia/.­
oxide. This absence of a dose-response relationship 
may be explained by the fact that the high glibencla­
mide dose ultimately induced an increase in systemic
lator response. The interaction between glibencla- insulin levels, although this small rise is not expected  
mide and diazoxide appeared to be of a specific char- to induce effects on forearm blood flow [36]. Othei 
acter because glibenclamide did not attenuate the va­
sodilator response to SNP. Moreover, the new SU de­
rivative glimepiride showed no interaction with diaz­
oxide in our human in vivo model.
Intraarterial infusion of low-dose glibenclamide 
resulted in regional concentrations of = 2 0 0  ng/ml, 
which even fell to =50  ng/ml during subsequent va­
sodilation as a result of dilution related to the higher 
flows, that agree with the systemic serum concentra­
tions reached in NIDDM  throughout the day after 
oral treatment with glibenclamide [2 0 , 2 1 ].
Several in vitro studies in animal models have 
demonstrated that SU derivatives are able to block 
the vasodilator effects of a wide range of KAn. chan­
nel openers [3, 31, 32]. However, this does not neces­
sarily hold for the human in vivo situation, especially 
because the high protein binding of glibenclamide 
may cause free concentrations to be too low to inter­
act with cardiovascular KAT1, channels [21, 33). As 
such, we think that our observations are remarkable 
because they show for the first time that glibencla­
mide may interfere with vascular K,vn. channels in 
man at clinically relevant concentrations.
The phenomenon of differences between the affin-
possible explanations include: a maximal inhibitory 
effect already at the low glibenclamide concentra- 
tion, the difference in study groups between the low- 
and high-doses and poor selectivity for the KAT1, 
channel of the vasodilator diazoxide. However, none 
i)f these explanations are very likely [31, 37], It is 
also unlikely that there is a delay because sulphonyl-
»  »  I +
urea derivatives have to diffuse into the cell mem­
brane before reaching their receptor |38|, since the 
results of the post-hoc tests showed a significant inhi­
bition of the last diazoxide dose by the low-dose glib­
enclamide in contrast to the high-dose glibenclamide.
We did not find any effect of ulibenclamide on the
*4 V i
baseline FBF. This is in accordance with reports of a 
low open-state probability of the KA ( channel in vas­
cular smooth muscle under baseline conditions (4|.
Patients with NIDDM  are relatively often exposed 
to myocardial ischaemia. During chronic treatment 
glibenclamide concentrations are close lo those 
reached in the forearm in our study ( l , ,V)|, suggesting 
that at therapeutic concentrations glibenclamide has 
the potential to affect ischaemia-induced opening of 
cardiovascular K,vll. channels. Blockade of KAn> 
channels by glibenclamide has been shown to impair
ity of glibenclamidc to KAn. channels in different tis- KAI1, channel-mediated protective effects [7. 14]. A 
sues probably reflects the heterogeneity of these recent study in man supports this view by showing 
channels [34]. This implies that more selective agents that 10 mg of oral glibenclamide abolished ischaemic
preconditioning during angioplasty 113 1. Nonetheless 
it remains to be determined whether the acute effects 
of glibenclamide on pharmacological opening of vas-
should be able to block pancreatic KA n. channels suf­
ficiently without interfering with cardiovascular KATI. 
channels. This selectivity could be more distinct be- 
cause of the recently discovered different binding cular KAn, channels as observed in our study can be 
sites for SU derivatives [2ft, 35]. The newly developed extrapolated to the chronic effects of glibenclamide 
SU derivative glimepiride has been shown to possess on ischaemia-mediated opening of KAn, channels 
such a selectivity in animal experiments [15, 16. 2 ft].
The present study shows that this selectivity is also 
true in the in vivo situation in humans, because in
during treatment of NIDDM patients. Further it has 
to be emphasized that our results on the vascular ef­
fects of glibenclamide do not neccessarilv hold for
contrast to glibenclamide, the effects of the SU deriv- myocardial KAlr channels.
ative glimepiride could not be distinguished from that 
of placebo. The absence of a vascular effect of glim­
epiride as opposed to glihendamide cannot be attrib­
uted to a relatively low dosing for glimepiride, since
'Hie closure of KAn. channels by SU derivatives 
has heen shown to decrease the occurrence of ven­
tricular fibrillation durimi or after ischaemia because 
it reduces the ischaemia-related K ‘ efflux from the
myocardium [40, 41]. This dichotomous character of 
SU derivatives, with de tri men tal effects on contrac­
tile function and infarct size as well as beneficial ef­
fects on the incidence of fatal arrhythmias, may ham- 
per conclusions from epidemiological studies as long 
as the relevant end points such as ventricular fibrilla­
tion and ejection fraction are not specifically in­
cluded.
We conclude that the classical sulphonylurea de­
rivative glibenclamide is able to specifically block 
vascular K,yn* channels in humans at concentrations 
that occur in NIDDM  patients using glibenclamide 
orally. In contrast, the newly developed sulphonyl­
urea derivative glimepiride showed no evidence for 
this interaction. Because of the role of KATP channel- 
opening in the pathophysiology of myocardial ischae­
mia and infarction, our observations warrant further 
studies on the clinical consequences of classic versus 
new sulphonylurea drugs in the treatment of 
NIDDM.
This study was supported by the Diabetes 
Fonds Nederland, urani nr. 93.101, and by Hoechst Holland
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